Activation of c-Jun by human cytomegalovirus UL42 through JNK activation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 24 01 2020
accepted: 17 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 6 8 2020
Statut: epublish

Résumé

c-Jun is a major component of the AP-1 transactivator complex. In this report, we demonstrated that AP-1 was activated by the expression of UL42, a human cytomegalovirus-encoded membrane protein that has two PPXY (PY) motifs and a C-terminal transmembrane domain (TMD). Although UL42 interacts with Itch, an ubiquitin E3 ligase, through the PY motifs, UL42 phosphorylated c-Jun and c-Jun N-terminal kinase (JNK) in the absence of any interaction with Itch. Experiments using mutated versions of UL42 suggest the importance of the carboxyl half (a.a. 52-124) of UL42 for the activation of the JNK signaling, while C-terminal TMD alone is not sufficient. Thus, we hypothesize that UL42 plays a role in the activation of JNK signaling in HCMV-infected cells. (118 words).

Identifiants

pubmed: 32369499
doi: 10.1371/journal.pone.0232635
pii: PONE-D-20-02197
pmc: PMC7199950
doi:

Substances chimiques

JUN protein, human 0
Proto-Oncogene Proteins c-jun 0
Repressor Proteins 0
Viral Proteins 0
ITCH protein, human EC 2.3.2.26
Ubiquitin-Protein Ligases EC 2.3.2.27
JNK Mitogen-Activated Protein Kinases EC 2.7.11.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232635

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Pathog. 2019 May 20;15(5):e1007691
pubmed: 31107917
Microbiol Mol Biol Rev. 2016 Jul 27;80(3):793-835
pubmed: 27466283
J Virol. 2002 Jul;76(13):6718-28
pubmed: 12050385
Gene. 1991 Dec 15;108(2):193-9
pubmed: 1660837
Microbiol Immunol. 2018 Oct;62(10):651-658
pubmed: 30187945
J Gen Virol. 1999 Apr;80 ( Pt 4):961-969
pubmed: 10211966
J Virol. 2005 Jan;79(1):95-105
pubmed: 15596805
J Virol. 1991 Dec;65(12):6724-34
pubmed: 1658371
Biochem Biophys Res Commun. 2011 Apr 22;407(4):735-40
pubmed: 21439937
J Virol. 2017 Aug 10;91(17):
pubmed: 28637759
Virology. 2010 Sep 30;405(2):280-8
pubmed: 20598727
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8
pubmed: 14623981
Sci Rep. 2018 Mar 13;8(1):4447
pubmed: 29535361
J Biol Chem. 2009 Oct 23;284(43):29399-404
pubmed: 19737936
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Mol Biosyst. 2014 Jul;10(7):1643-57
pubmed: 24457516
Protein Cell. 2011 Nov;2(11):889-98
pubmed: 22180088
J Virol. 2009 Apr;83(8):3463-74
pubmed: 19193809
Nature. 1991 Dec 12;354(6353):494-6
pubmed: 1749429
J Immunol. 2001 Nov 15;167(10):5805-13
pubmed: 11698454
J Med Virol. 2015 Dec;87(12):2135-44
pubmed: 26058558
J Gen Virol. 2016 Jan;97(1):196-208
pubmed: 26555021
Nature. 1991 Oct 17;353(6345):670-4
pubmed: 1922387

Auteurs

Tetsuo Koshizuka (T)

Microbiology and Immunology, Gifu Pharmaceutical University, Gifu, Japan.

Naoki Inoue (N)

Microbiology and Immunology, Gifu Pharmaceutical University, Gifu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH